Cantor Fitzgerald Predicts MiMedx Group FY2025 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for MiMedx Group in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings of $0.33 per share for the year. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.05 by $0.02. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The business had revenue of $84.06 million for the quarter, compared to analyst estimates of $81.00 million. During the same quarter in the previous year, the firm earned $0.05 EPS.

Separately, StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, MiMedx Group has an average rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Price Performance

Shares of MDXG stock opened at $9.03 on Wednesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The company has a market capitalization of $1.33 billion, a PE ratio of 16.42 and a beta of 1.96. The firm’s 50-day moving average is $9.22 and its two-hundred day moving average is $7.45. MiMedx Group has a 12 month low of $5.47 and a 12 month high of $10.14.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MDXG. SG Americas Securities LLC lifted its holdings in shares of MiMedx Group by 79.9% in the 4th quarter. SG Americas Securities LLC now owns 83,385 shares of the company’s stock worth $802,000 after acquiring an additional 37,031 shares during the last quarter. Fiduciary Alliance LLC purchased a new stake in MiMedx Group in the fourth quarter valued at approximately $160,000. JPMorgan Chase & Co. lifted its stake in MiMedx Group by 265.4% during the third quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock worth $1,757,000 after purchasing an additional 215,995 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of MiMedx Group by 6.3% during the third quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock worth $328,000 after buying an additional 3,292 shares during the period. Finally, SkyView Investment Advisors LLC grew its position in MiMedx Group by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock valued at $77,000 after acquiring an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.